These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 33244601)

  • 1. Rituximab for the treatment of systemic sclerosis-interstitial lung disease.
    Hughes M; Denton CP; Khanna D
    Rheumatology (Oxford); 2021 Feb; 60(2):489-491. PubMed ID: 33244601
    [No Abstract]   [Full Text] [Related]  

  • 2. Successful treatment with rituximab in a Japanese patient with systemic sclerosis-associated interstitial lung disease resistant to oral steroid and cyclophosphamide.
    Numajiri H; Yoshizaki A; Ebata S; Fukasawa T; Yamashita T; Takahashi T; Taniguchi T; Asano Y; Sato S
    J Dermatol; 2018 Jun; 45(6):e140-e141. PubMed ID: 29265579
    [No Abstract]   [Full Text] [Related]  

  • 3. Rituximab therapy is more effective than cyclophosphamide therapy for Japanese patients with anti-topoisomerase I-positive systemic sclerosis-associated interstitial lung disease.
    Ebata S; Yoshizaki A; Fukasawa T; Miura S; Takahashi T; Sumida H; Asano Y; Sato S
    J Dermatol; 2019 Nov; 46(11):1006-1013. PubMed ID: 31502326
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Unprecedented success of rituximab therapy for prednisolone- and immunosuppressant-resistant systemic sclerosis-associated interstitial lung disease.
    Ebata S; Yoshizaki A; Fukasawa T; Nakamura K; Yamashita T; Miura S; Saigusa R; Ichimura Y; Takahashi T; Hirabayashi M; Taniguchi T; Akamata K; Asano Y; Sato S
    Scand J Rheumatol; 2017 May; 46(3):247-252. PubMed ID: 27900875
    [No Abstract]   [Full Text] [Related]  

  • 5. Rituximab in the treatment of systemic sclerosis-associated interstitial lung disease: comment on the article by Yoo.
    Daoussis D; Andonopoulos AP
    Rheumatol Int; 2011 Jun; 31(6):841-2. PubMed ID: 20376665
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Is biological therapy in systemic sclerosis the answer?
    Misra DP; Ahmed S; Agarwal V
    Rheumatol Int; 2020 May; 40(5):679-694. PubMed ID: 31960079
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy and safety of rituximab in systemic sclerosis: French retrospective study and literature review.
    Thiebaut M; Launay D; Rivière S; Mahévas T; Bellakhal S; Hachulla E; Fain O; Mekinian A
    Autoimmun Rev; 2018 Jun; 17(6):582-587. PubMed ID: 29635080
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A multicenter, open-label, comparative study of B-cell depletion therapy with Rituximab for systemic sclerosis-associated interstitial lung disease.
    Daoussis D; Melissaropoulos K; Sakellaropoulos G; Antonopoulos I; Markatseli TE; Simopoulou T; Georgiou P; Andonopoulos AP; Drosos AA; Sakkas L; Liossis SN
    Semin Arthritis Rheum; 2017 Apr; 46(5):625-631. PubMed ID: 27839742
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combination therapy with rituximab and mycophenolate mofetil in systemic sclerosis. A single-centre case series study.
    Fraticelli P; Fischetti C; Salaffi F; Carotti M; Mattioli M; Pomponio G; Gabrielli A
    Clin Exp Rheumatol; 2018; 36 Suppl 113(4):142-145. PubMed ID: 30277864
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment Algorithms for Systemic Sclerosis According to Experts.
    Fernández-Codina A; Walker KM; Pope JE;
    Arthritis Rheumatol; 2018 Nov; 70(11):1820-1828. PubMed ID: 29781586
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [New developments in systemic sclerosis-associated interstitial lung disease].
    Humair G; Daccord C; Beigelman-Aubry C; Lazor R
    Rev Med Suisse; 2020 Nov; 16(715):2218-2223. PubMed ID: 33206479
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A new therapy for systemic sclerosis-associated interstitial lung disease.
    Kondoh Y
    Respir Investig; 2020 Jul; 58(4):227-229. PubMed ID: 32451295
    [No Abstract]   [Full Text] [Related]  

  • 13. The efficacy of treatment for systemic sclerosis interstitial lung disease: results from a meta-analysis.
    Broad K; Pope JE
    Med Sci Monit; 2010 Sep; 16(9):RA187-90. PubMed ID: 20802426
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects and safety of rituximab in systemic sclerosis: an analysis from the European Scleroderma Trial and Research (EUSTAR) group.
    Jordan S; Distler JH; Maurer B; Huscher D; van Laar JM; Allanore Y; Distler O;
    Ann Rheum Dis; 2015 Jun; 74(6):1188-94. PubMed ID: 24442885
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Cyclophosphamide in scleroderma lung disease.
    Sullivan KM; McSweeney PA; Nash RA
    N Engl J Med; 2006 Sep; 355(11):1173-4; author reply 1174. PubMed ID: 16977701
    [No Abstract]   [Full Text] [Related]  

  • 16. Progressive systemic sclerosis and the lung.
    Veeraraghavan S; Sharma OP
    Curr Opin Pulm Med; 1998 Sep; 4(5):305-9. PubMed ID: 10813207
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Immunosuppressive treatment of the pulmonary manifestations of progressive systemic sclerosis.
    Vallance DK; Lynch JP; McCune WJ
    Curr Opin Rheumatol; 1995 May; 7(3):174-82. PubMed ID: 7612408
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Cyclophosphamide in scleroderma lung disease.
    Andreu JL; Silva L
    N Engl J Med; 2006 Sep; 355(11):1173; author reply 1174. PubMed ID: 16977700
    [No Abstract]   [Full Text] [Related]  

  • 19. Cyclosporin A in progressive system sclerosis.
    Constantopoulos A
    Acta Paediatr; 1995 Jan; 84(1):69. PubMed ID: 7734904
    [No Abstract]   [Full Text] [Related]  

  • 20. Cyclosporin A in progressive system sclerosis.
    Constantopoulos A; Dracou C; Tsoumakas C
    Acta Paediatr; 1995 Jun; 84(6):604. PubMed ID: 7670238
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 11.